60 results
8-K
EX-3.2
IMGN
Immunogen, Inc.
12 Feb 24
Termination of a Material Definitive Agreement
7:52am
, then a special meeting in lieu of an annual meeting may be held on a date determined by the Board of Directors and any action taken at such meeting … , to demand a special meeting, to vote, or to take any other action. If a record date for a specific action is not fixed by the Board of Directors
8-K
IMGN
Immunogen, Inc.
31 Jan 24
Submission of Matters to a Vote of Security Holders
4:12pm
a virtual special meeting of shareholders (the “Special Meeting”) to consider and vote on the proposals set forth in the definitive proxy statement … .
As of the close of business on December 29, 2023, the record date for the shareholders entitled to vote at the Special Meeting, there were a total
DEFA14A
IMGN
Immunogen, Inc.
24 Jan 24
Additional proxy soliciting materials
4:57pm
shareholders in connection with the Merger or the timing of the special meeting of ImmunoGen shareholders (the “Special Meeting”) to be held virtually … on January 31, 2024, at 9:00 a.m. Eastern Time. ImmunoGen shareholders will be able to virtually attend and vote at the Special Meeting via the internet
8-K
IMGN
Immunogen, Inc.
24 Jan 24
Other Events
4:55pm
will not change the consideration to be paid to ImmunoGen shareholders in connection with the Merger or the timing of the special meeting of ImmunoGen shareholders … (the “Special Meeting”) to be held virtually on January 31, 2024, at 9:00 a.m. Eastern Time. ImmunoGen shareholders will be able to virtually attend
DEFM14A
IMGN
Immunogen, Inc.
2 Jan 24
Proxy related to merger
4:26pm
January 2, 2024
Dear Shareholder:
You are cordially invited to attend a virtual special meeting (including any adjournments or postponements thereof … , the “Special Meeting”) of holders of shares of common stock, par value $0.01 per share (the “Company Common Stock”), of ImmunoGen, Inc., a Massachusetts
PREM14A
mgj 3bupt667iu0g7v
21 Dec 23
Preliminary proxy related to merger
4:52pm
DEFA14A
EX-2.1
hdltt 5fmo0m3cu
30 Nov 23
Additional proxy soliciting materials
4:07pm
8-K
EX-2.1
npzkb3ldmvb o2
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
EX-3.1
qdeh63iqxb18 91nc
16 Jun 23
Amendments to Articles of Incorporation or Bylaws
4:15pm
8-K
k89npt
16 Jun 23
Amendments to Articles of Incorporation or Bylaws
4:15pm
424B5
h1cu ywxdsn
5 May 23
Prospectus supplement for primary offering
4:49pm
424B5
u9fbi awacxdi59
3 May 23
Prospectus supplement for primary offering
4:05pm
424B5
hqiln67sf9wtcocdcjy
3 Dec 21
Prospectus supplement for primary offering
4:06pm
424B5
jl07k3d
30 Nov 21
Prospectus supplement for primary offering
5:12pm
424B5
53gg0 iqlcjg3n
12 Aug 21
Prospectus supplement for primary offering
10:11am